Source comparison
CJC-1295 With DAC vs CJC-1295 Without DAC (Mod GRF 1-29)
The terminology around CJC-1295 peptide is a common source of confusion in research settings. CJC-1295 with DAC refers to the original formulation developed by ConjuChem Biotechnologies, which includes the maleimidoproprionic acid linker that binds albumin. CJ
This comparison does not assign a generated winner or score.
- The terminology around CJC-1295 peptide is a common source of confusion in research settings. CJC-1295 with DAC refers to the original formulation developed by ConjuChem Biotechnologies, which includes the maleimidoproprionic acid linker that binds albumin. CJC-1295 without DAC. More accurately called Modified GRF 1-29 or Mod GRF 1-29. Is the same 30-amino-acid sequence with the four DPP-4-resistant substitutions but without the albumin-binding DAC group. These are not interchangeable compounds. They have different half-lives, different dosing protocols, and different research applications.
- CJC-1295 with DAC has a half-life of approximately 6–8 days, making it suitable for research protocols that require sustained baseline elevation of GH-releasing activity with infrequent dosing. Modified GRF 1-29, lacking the DAC modification, has a half-life of approximately 30 minutes. Longer than native GHRH but still requiring administration multiple times per day to maintain effect. The functional difference is dosing frequency: CJC-1295 with DAC is typically administered once or twice weekly in research models, while Mod GRF 1-29 is dosed 1–3 times daily, often in conjunction with a growth hormone-releasing peptide (GHRP) like ipamorelin to amplify pulsatile secretion.
- Research teams often combine CJC-1295 with ipamorelin in controlled studies examining synergistic effects on GH secretion. Ipamorelin is a ghrelin receptor agonist that stimulates GH release through a different pathway (ghrelin receptor at the pituitary and hypothalamus) than CJC-1295 (GHRH receptor). When used together, these peptides amplify both the amplitude and frequency of GH pulses without causing the cortisol or prolactin elevation seen with older GHRPs like GHRP-6. The combination protocol typically involves daily ipamorelin dosing alongside once or twice-weekly CJC-1295 with DAC administration, creating a sustained baseline elevation (from CJC-1295) with additional acute pulses (from ipamorelin).